VT104

Cat. No.:	HY-134956
CAS No.:	2417718-25-1
Molecular Formula:	$C_{25}H_{19}F_3N_2O$
Molecular Weight:	420.43
Target:	YAP
Pathway:	Stem Cell/Wnt
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (237.85 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.3785 mL	11.8926 mL	23.7852 mL
5 mM	0.4757 mL	2.3785 mL	4.7570 mL
10 mM	0.2379 mL	1.1893 mL	2.3785 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer[1][2].

In Vitro

VT104 (0-1000 nM) inhibits proliferation of NF2 mutant/defective cell line[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

VT104 (0.3-3 mg/kg; p.o.; NCI-H226-tumor bearing mice) blocks growth of NF2-deficient mesothelioma xenografts[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H226-tumor bearing mice[1]
Dosage:	0.3, 1, and 3 mg/kg
Administration:	Oral administration

Result:	Blocked NCI-H226 tumor growth in mice in dose-dependent manner.

REFERENCES

[1]. Tang TT, et, al. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Mol Cancer Ther. 2021 Jun;20(6):986-998.

[2]. Barry ER, et, al. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine. Cells. 2021 Oct 11;10(10):2715.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA